#United States #New York #Class Action #Investor Rights #Soleno Therapeutics

Legal Action in Focus: Soleno Therapeutics Class Action

In a significant development for investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO), Bronstein, Gewirtz & Grossman LLC, a prominent law firm specializing in investor rights, has filed a class action lawsuit against the company and certain of its executives. This legal action arises from alleged violations of federal securities laws impacting those who acquired Soleno securities between March 26, 2025, and November 4, 2025.

Background

The essence of the lawsuit is to recover damages for investors who believe they have been harmed due to the defendants' actions or lack thereof during the defined Class Period. According to the firm's announcement, the complaint centers around the alleged misrepresentation by Soleno regarding its Phase 3 clinical trial for DCCR, a treatment intended to mitigate the impact of hyperphagia in patients with Prader-Willi Syndrome (PWS).

Allegations of Safety Concerns

The complaint details that throughout the Class Period, the executives at Soleno purportedly failed to disclose critical safety concerns related to the administration of DCCR. Specific alleged issues include systematic downplaying of evidence that indicated significant health risks, particularly concerning excess fluid retention among clinical trial participants. This omission implies that the treatment might have been significantly less safe than what was communicated to the public and potential investors.

Furthermore, the claim suggests that the unrevealed safety risks would lead to lower commercial viability for DCCR once it hit the market. Investors are cautioned about factors that could influence market performance, including patient discontinuation rates, prescriber hesitancy, and adverse regulatory actions.

Next Steps for Investors

Those who believe they have suffered financial losses from their investments in Soleno are encouraged to take action. The law firm offers a straightforward process for affected investors looking to join this class action. Interested parties can find detailed information and consult the Complaint by visiting Bronstein, Gewirtz & Grossman's dedicated web page for this case at bgandg.com/SLNO.

The law firm emphasizes that participation in this class action does not require individuals to risk their funds upfront, as it operates on a contingency basis. This means if the firm successfully recovers damages, their fees will be taken from the awarded amount. Otherwise, investors bear no financial responsibility for legal fees incurred.

Why Choose Bronstein, Gewirtz & Grossman?

In the realm of investor rights, Bronstein, Gewirtz & Grossman boasts a robust reputation, having recovered substantial settlements for investors through various securities fraud class actions over the years. Founding Partner Peretz Bronstein expressed a commitment to uphold corporate accountability and investor capital integrity, reinforcing the firm’s dedication to restoring confidence in the financial markets.

As legal proceedings continue, impacted investors should remain vigilant and consider their options carefully. The deadline for potential lead plaintiffs to formalize their participation in this class action is May 5, 2026. For any legal inquiries or further assistance, investors can reach out to Peretz Bronstein or Client Relations Manager Nathan Miller at the contact number provided.

Conclusion

Investors in Soleno Therapeutics, facing potential losses due to alleged mismanagement and unclear communication from the company's leadership, have a pivotal chance to assert their rights through this class action lawsuit. With Bronstein, Gewirtz & Grossman's proven track record, stakeholders are presented with a reliable avenue to seek justice and possible financial recovery for their investments.